Rocket Pharmaceuticals (RCKT) Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for Treatment of Danon Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. SYNA
2. ON
3. SPY
4. MU
5. AAPL
6. VEON
7. SPCX
8. LFTO
9. INIO
10. DRI

Go back to Rocket Pharmaceuticals (RCKT) Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for Treatment of Danon Disease
(NASDAQ: RCKT) Delayed: 3.25 --0 (-0%)
Previous Close $3.25    52 Week High $ 
Open $3.25    52 Week Low $ 
Day High $3.25    P/E N/A 
Day Low $3.25    EPS $ 
Volume 426